Skip to main content

Champions Oncology to Announce Second Quarter Financial Results on Tuesday, December 13, 2022

HACKENSACK, NJ / ACCESSWIRE / December 9, 2022 / Champions Oncology, Inc. (CSBR), a leading global technology-enabled biotech that is transforming drug discovery through innovative AI-driven pharmaco-pheno-multiomic integration, will report its financial and operational results for the second quarter ended October 31, 2022, on Tuesday, December 13, 2022, after market close. The company will host a conference call to discuss the results that day at 4:30 P.M. EST (1:30 P.M. PST). To join the call dial 877-545-0523 (Domestic) or 973-528-0016 (International) and enter the access code 541646. A replay of the call will be available by dialing 877-481-4010 (Domestic) or 919-882-2331 (International) and entering passcode: 47307, or by accessing the investors section of the company's website within 72 hours.

About Champions Oncology, Inc.

Champions Oncology is a technology-driven research organization that develops innovative therapeutics against cancer targets, offers groundbreaking research software as a service, and provides end-to-end R&D services to biopharma organizations. Champions Oncology is actively engaged in the transformation of drug discovery through a novel approach of pharmaco-pheno-multiomic integration. For more information, please visit www.ChampionsOncology.com.

SOURCE: Champions Oncology, Inc.



View source version on accesswire.com:
https://www.accesswire.com/731165/Champions-Oncology-to-Announce-Second-Quarter-Financial-Results-on-Tuesday-December-13-2022

Recent Quotes

View More
Symbol Price Change (%)
AMZN  226.37
-3.91 (-1.70%)
AAPL  277.91
-0.12 (-0.04%)
AMD  212.30
-9.13 (-4.12%)
BAC  55.06
+0.50 (0.93%)
GOOG  310.64
-3.06 (-0.97%)
META  642.93
-9.78 (-1.50%)
MSFT  477.81
-5.66 (-1.17%)
NVDA  176.80
-4.13 (-2.28%)
ORCL  188.95
-9.90 (-4.98%)
TSLA  446.16
-0.73 (-0.16%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.